Cassella James V 4
4 · Trevi Therapeutics, Inc. · Filed Feb 20, 2025
Insider Transaction Report
Form 4
Cassella James V
Chief Development Officer
Transactions
- Award
Stock Option (right to buy)
2025-02-18+257,500→ 257,500 totalExercise: $4.22Exp: 2035-02-17→ Common Stock (257,500 underlying)
Footnotes (1)
- [F1]This option was granted on February 18, 2025. The 257,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.